Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 09:05 pm
Share
Xencor, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 59.16 million compared to USD 27.3 million a year ago. Net loss was USD 24.27 million compared to USD 32.76 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.55 a year ago.
For the nine months, sales was USD 123.65 million compared to USD 142.97 million a year ago. Net loss was USD 106.99 million compared to USD 43.14 million a year ago. Basic loss per share from continuing operations was USD 1.77 compared to USD 0.72 a year ago.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
XENCOR, INC. 
